On Aug. 24, 2020, Catalent announced that it had contracted to provide drug substance manufacturing to AstraZeneca for the University of Oxfordﾒs adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalentﾒs commercial gene therapy manufacturing facility located in Harmans, Maryland.

The adenovirus vector-based vaccine candidate, AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.